nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—CYP1A2—Flutamide—prostate cancer	0.0652	0.347	CbGbCtD
Pentoxifylline—CYP1A2—Estrone—prostate cancer	0.0471	0.251	CbGbCtD
Pentoxifylline—CYP1A2—Conjugated Estrogens—prostate cancer	0.0308	0.164	CbGbCtD
Pentoxifylline—CYP1A2—Estradiol—prostate cancer	0.0271	0.144	CbGbCtD
Pentoxifylline—PDE5A—penis—prostate cancer	0.0231	0.163	CbGeAlD
Pentoxifylline—CYP1A2—Etoposide—prostate cancer	0.0177	0.0941	CbGbCtD
Pentoxifylline—NT5E—prostate gland—prostate cancer	0.00851	0.0601	CbGeAlD
Pentoxifylline—ADORA2B—prostate gland—prostate cancer	0.00729	0.0514	CbGeAlD
Pentoxifylline—CYP1A2—urine—prostate cancer	0.00662	0.0468	CbGeAlD
Pentoxifylline—PDE4A—prostate gland—prostate cancer	0.00649	0.0459	CbGeAlD
Pentoxifylline—NT5E—epithelium—prostate cancer	0.00625	0.0441	CbGeAlD
Pentoxifylline—NT5E—renal system—prostate cancer	0.0058	0.0409	CbGeAlD
Pentoxifylline—NT5E—urethra—prostate cancer	0.0057	0.0402	CbGeAlD
Pentoxifylline—PDE5A—prostate gland—prostate cancer	0.00552	0.039	CbGeAlD
Pentoxifylline—ADORA2B—urethra—prostate cancer	0.00488	0.0344	CbGeAlD
Pentoxifylline—NT5E—bone marrow—prostate cancer	0.00438	0.031	CbGeAlD
Pentoxifylline—PDE5A—epithelium—prostate cancer	0.00406	0.0287	CbGeAlD
Pentoxifylline—PDE4B—prostate gland—prostate cancer	0.00387	0.0273	CbGeAlD
Pentoxifylline—PDE5A—renal system—prostate cancer	0.00376	0.0266	CbGeAlD
Pentoxifylline—NT5E—testis—prostate cancer	0.00375	0.0265	CbGeAlD
Pentoxifylline—PDE5A—urethra—prostate cancer	0.0037	0.0261	CbGeAlD
Pentoxifylline—Caffeine—PRKDC—prostate cancer	0.00366	0.243	CrCbGaD
Pentoxifylline—ADORA1—renal system—prostate cancer	0.00357	0.0252	CbGeAlD
Pentoxifylline—ADORA1—urethra—prostate cancer	0.0035	0.0247	CbGeAlD
Pentoxifylline—ADORA2B—testis—prostate cancer	0.00321	0.0227	CbGeAlD
Pentoxifylline—PDE4A—testis—prostate cancer	0.00286	0.0202	CbGeAlD
Pentoxifylline—NT5E—lymph node—prostate cancer	0.00272	0.0192	CbGeAlD
Pentoxifylline—ADORA2A—testis—prostate cancer	0.00267	0.0189	CbGeAlD
Pentoxifylline—PDE4B—urethra—prostate cancer	0.00259	0.0183	CbGeAlD
Pentoxifylline—PDE5A—testis—prostate cancer	0.00243	0.0172	CbGeAlD
Pentoxifylline—ADORA1—testis—prostate cancer	0.00231	0.0163	CbGeAlD
Pentoxifylline—Caffeine—ATM—prostate cancer	0.0021	0.139	CrCbGaD
Pentoxifylline—PDE4A—lymph node—prostate cancer	0.00207	0.0146	CbGeAlD
Pentoxifylline—PDE4B—bone marrow—prostate cancer	0.002	0.0141	CbGeAlD
Pentoxifylline—Caffeine—PIK3CD—prostate cancer	0.00193	0.128	CrCbGaD
Pentoxifylline—Caffeine—PIK3CB—prostate cancer	0.00193	0.128	CrCbGaD
Pentoxifylline—PDE5A—lymph node—prostate cancer	0.00176	0.0125	CbGeAlD
Pentoxifylline—PDE4B—testis—prostate cancer	0.00171	0.012	CbGeAlD
Pentoxifylline—ADORA1—lymph node—prostate cancer	0.00167	0.0118	CbGeAlD
Pentoxifylline—CYP1A2—renal system—prostate cancer	0.00162	0.0114	CbGeAlD
Pentoxifylline—Caffeine—PIK3CA—prostate cancer	0.00149	0.0986	CrCbGaD
Pentoxifylline—Dyphylline—PDE4D—prostate cancer	0.00139	0.0922	CrCbGaD
Pentoxifylline—PDE4B—lymph node—prostate cancer	0.00124	0.00873	CbGeAlD
Pentoxifylline—Theobromine—CYP2E1—prostate cancer	0.000645	0.0427	CrCbGaD
Pentoxifylline—Caffeine—CYP1B1—prostate cancer	0.000606	0.0401	CrCbGaD
Pentoxifylline—Caffeine—CYP3A5—prostate cancer	0.000483	0.032	CrCbGaD
Pentoxifylline—Caffeine—CYP2E1—prostate cancer	0.000332	0.022	CrCbGaD
Pentoxifylline—Caffeine—CYP1A1—prostate cancer	0.000327	0.0217	CrCbGaD
Pentoxifylline—Caffeine—CYP3A4—prostate cancer	0.000209	0.0138	CrCbGaD
Pentoxifylline—Gastrointestinal pain—Etoposide—prostate cancer	0.000172	0.000424	CcSEcCtD
Pentoxifylline—Shock—Docetaxel—prostate cancer	0.000172	0.000424	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Prednisone—prostate cancer	0.000172	0.000423	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Docetaxel—prostate cancer	0.000172	0.000422	CcSEcCtD
Pentoxifylline—Rash—Estradiol—prostate cancer	0.000172	0.000422	CcSEcCtD
Pentoxifylline—Infestation NOS—Doxorubicin—prostate cancer	0.000171	0.000422	CcSEcCtD
Pentoxifylline—Infestation—Doxorubicin—prostate cancer	0.000171	0.000422	CcSEcCtD
Pentoxifylline—Drowsiness—Doxorubicin—prostate cancer	0.000171	0.000422	CcSEcCtD
Pentoxifylline—Dermatitis—Estradiol—prostate cancer	0.000171	0.000422	CcSEcCtD
Pentoxifylline—Anaemia—Prednisone—prostate cancer	0.000171	0.000421	CcSEcCtD
Pentoxifylline—Confusional state—Capecitabine—prostate cancer	0.000171	0.000421	CcSEcCtD
Pentoxifylline—Tachycardia—Docetaxel—prostate cancer	0.000171	0.000421	CcSEcCtD
Pentoxifylline—Headache—Estradiol—prostate cancer	0.00017	0.00042	CcSEcCtD
Pentoxifylline—Skin disorder—Docetaxel—prostate cancer	0.00017	0.000419	CcSEcCtD
Pentoxifylline—Agitation—Prednisone—prostate cancer	0.00017	0.000419	CcSEcCtD
Pentoxifylline—Oedema—Capecitabine—prostate cancer	0.00017	0.000418	CcSEcCtD
Pentoxifylline—Angioedema—Prednisone—prostate cancer	0.000169	0.000416	CcSEcCtD
Pentoxifylline—Infection—Capecitabine—prostate cancer	0.000169	0.000415	CcSEcCtD
Pentoxifylline—Urticaria—Etoposide—prostate cancer	0.000168	0.000412	CcSEcCtD
Pentoxifylline—Haemoglobin—Epirubicin—prostate cancer	0.000167	0.000412	CcSEcCtD
Pentoxifylline—Jaundice—Doxorubicin—prostate cancer	0.000167	0.000411	CcSEcCtD
Pentoxifylline—Anorexia—Docetaxel—prostate cancer	0.000167	0.000411	CcSEcCtD
Pentoxifylline—Malaise—Prednisone—prostate cancer	0.000167	0.000411	CcSEcCtD
Pentoxifylline—Shock—Capecitabine—prostate cancer	0.000167	0.000411	CcSEcCtD
Pentoxifylline—Body temperature increased—Etoposide—prostate cancer	0.000167	0.00041	CcSEcCtD
Pentoxifylline—Abdominal pain—Etoposide—prostate cancer	0.000167	0.00041	CcSEcCtD
Pentoxifylline—Conjunctivitis—Doxorubicin—prostate cancer	0.000167	0.00041	CcSEcCtD
Pentoxifylline—Hepatitis—Epirubicin—prostate cancer	0.000166	0.00041	CcSEcCtD
Pentoxifylline—Haemorrhage—Epirubicin—prostate cancer	0.000166	0.00041	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Capecitabine—prostate cancer	0.000166	0.000409	CcSEcCtD
Pentoxifylline—Tachycardia—Capecitabine—prostate cancer	0.000166	0.000408	CcSEcCtD
Pentoxifylline—Skin disorder—Capecitabine—prostate cancer	0.000165	0.000406	CcSEcCtD
Pentoxifylline—Sweating—Doxorubicin—prostate cancer	0.000164	0.000405	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Capecitabine—prostate cancer	0.000164	0.000404	CcSEcCtD
Pentoxifylline—Hypotension—Docetaxel—prostate cancer	0.000164	0.000403	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000162	0.000399	CcSEcCtD
Pentoxifylline—Epistaxis—Doxorubicin—prostate cancer	0.000162	0.000398	CcSEcCtD
Pentoxifylline—Anorexia—Capecitabine—prostate cancer	0.000162	0.000398	CcSEcCtD
Pentoxifylline—Nausea—Estradiol—prostate cancer	0.000162	0.000398	CcSEcCtD
Pentoxifylline—Vomiting—Mitoxantrone—prostate cancer	0.000161	0.000397	CcSEcCtD
Pentoxifylline—Convulsion—Prednisone—prostate cancer	0.00016	0.000395	CcSEcCtD
Pentoxifylline—Hypertension—Prednisone—prostate cancer	0.00016	0.000394	CcSEcCtD
Pentoxifylline—Rash—Mitoxantrone—prostate cancer	0.00016	0.000393	CcSEcCtD
Pentoxifylline—Dermatitis—Mitoxantrone—prostate cancer	0.00016	0.000393	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.00016	0.000393	CcSEcCtD
Pentoxifylline—Headache—Mitoxantrone—prostate cancer	0.000159	0.000391	CcSEcCtD
Pentoxifylline—Hypotension—Capecitabine—prostate cancer	0.000159	0.00039	CcSEcCtD
Pentoxifylline—Insomnia—Docetaxel—prostate cancer	0.000159	0.00039	CcSEcCtD
Pentoxifylline—Myalgia—Prednisone—prostate cancer	0.000158	0.000388	CcSEcCtD
Pentoxifylline—Anxiety—Prednisone—prostate cancer	0.000157	0.000387	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000157	0.000385	CcSEcCtD
Pentoxifylline—Dyspnoea—Docetaxel—prostate cancer	0.000156	0.000385	CcSEcCtD
Pentoxifylline—Somnolence—Docetaxel—prostate cancer	0.000156	0.000383	CcSEcCtD
Pentoxifylline—Discomfort—Prednisone—prostate cancer	0.000156	0.000383	CcSEcCtD
Pentoxifylline—Hypersensitivity—Etoposide—prostate cancer	0.000155	0.000382	CcSEcCtD
Pentoxifylline—Haemoglobin—Doxorubicin—prostate cancer	0.000155	0.000381	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000155	0.000381	CcSEcCtD
Pentoxifylline—Flushing—Epirubicin—prostate cancer	0.000154	0.00038	CcSEcCtD
Pentoxifylline—Dyspepsia—Docetaxel—prostate cancer	0.000154	0.00038	CcSEcCtD
Pentoxifylline—Haemorrhage—Doxorubicin—prostate cancer	0.000154	0.000379	CcSEcCtD
Pentoxifylline—Hepatitis—Doxorubicin—prostate cancer	0.000154	0.000379	CcSEcCtD
Pentoxifylline—Insomnia—Capecitabine—prostate cancer	0.000153	0.000378	CcSEcCtD
Pentoxifylline—Decreased appetite—Docetaxel—prostate cancer	0.000152	0.000375	CcSEcCtD
Pentoxifylline—Asthenia—Etoposide—prostate cancer	0.000151	0.000372	CcSEcCtD
Pentoxifylline—Dyspnoea—Capecitabine—prostate cancer	0.000151	0.000372	CcSEcCtD
Pentoxifylline—Oedema—Prednisone—prostate cancer	0.000151	0.000372	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Prednisone—prostate cancer	0.000151	0.000372	CcSEcCtD
Pentoxifylline—Nausea—Mitoxantrone—prostate cancer	0.000151	0.000371	CcSEcCtD
Pentoxifylline—Immune system disorder—Epirubicin—prostate cancer	0.00015	0.00037	CcSEcCtD
Pentoxifylline—Infection—Prednisone—prostate cancer	0.00015	0.00037	CcSEcCtD
Pentoxifylline—Constipation—Docetaxel—prostate cancer	0.00015	0.000369	CcSEcCtD
Pentoxifylline—Dyspepsia—Capecitabine—prostate cancer	0.000149	0.000368	CcSEcCtD
Pentoxifylline—Pruritus—Etoposide—prostate cancer	0.000149	0.000367	CcSEcCtD
Pentoxifylline—Shock—Prednisone—prostate cancer	0.000149	0.000366	CcSEcCtD
Pentoxifylline—Arrhythmia—Epirubicin—prostate cancer	0.000149	0.000366	CcSEcCtD
Pentoxifylline—Tachycardia—Prednisone—prostate cancer	0.000148	0.000363	CcSEcCtD
Pentoxifylline—Decreased appetite—Capecitabine—prostate cancer	0.000147	0.000363	CcSEcCtD
Pentoxifylline—Skin disorder—Prednisone—prostate cancer	0.000147	0.000361	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Prednisone—prostate cancer	0.000146	0.00036	CcSEcCtD
Pentoxifylline—Constipation—Capecitabine—prostate cancer	0.000145	0.000357	CcSEcCtD
Pentoxifylline—Erythema—Epirubicin—prostate cancer	0.000145	0.000356	CcSEcCtD
Pentoxifylline—Feeling abnormal—Docetaxel—prostate cancer	0.000144	0.000355	CcSEcCtD
Pentoxifylline—Diarrhoea—Etoposide—prostate cancer	0.000144	0.000355	CcSEcCtD
Pentoxifylline—Anorexia—Prednisone—prostate cancer	0.000144	0.000355	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Docetaxel—prostate cancer	0.000143	0.000353	CcSEcCtD
Pentoxifylline—Flushing—Doxorubicin—prostate cancer	0.000143	0.000352	CcSEcCtD
Pentoxifylline—Flatulence—Epirubicin—prostate cancer	0.000143	0.000351	CcSEcCtD
Pentoxifylline—Tension—Epirubicin—prostate cancer	0.000142	0.00035	CcSEcCtD
Pentoxifylline—Dysgeusia—Epirubicin—prostate cancer	0.000142	0.000349	CcSEcCtD
Pentoxifylline—Nervousness—Epirubicin—prostate cancer	0.000141	0.000346	CcSEcCtD
Pentoxifylline—Back pain—Epirubicin—prostate cancer	0.00014	0.000345	CcSEcCtD
Pentoxifylline—Feeling abnormal—Capecitabine—prostate cancer	0.00014	0.000344	CcSEcCtD
Pentoxifylline—Dizziness—Etoposide—prostate cancer	0.000139	0.000343	CcSEcCtD
Pentoxifylline—Muscle spasms—Epirubicin—prostate cancer	0.000139	0.000343	CcSEcCtD
Pentoxifylline—Immune system disorder—Doxorubicin—prostate cancer	0.000139	0.000342	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Capecitabine—prostate cancer	0.000139	0.000342	CcSEcCtD
Pentoxifylline—Body temperature increased—Docetaxel—prostate cancer	0.000139	0.000341	CcSEcCtD
Pentoxifylline—Abdominal pain—Docetaxel—prostate cancer	0.000139	0.000341	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000138	0.000339	CcSEcCtD
Pentoxifylline—Arrhythmia—Doxorubicin—prostate cancer	0.000138	0.000339	CcSEcCtD
Pentoxifylline—Insomnia—Prednisone—prostate cancer	0.000137	0.000336	CcSEcCtD
Pentoxifylline—Vision blurred—Epirubicin—prostate cancer	0.000136	0.000336	CcSEcCtD
Pentoxifylline—Urticaria—Capecitabine—prostate cancer	0.000135	0.000332	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Epirubicin—prostate cancer	0.000134	0.000331	CcSEcCtD
Pentoxifylline—Abdominal pain—Capecitabine—prostate cancer	0.000134	0.00033	CcSEcCtD
Pentoxifylline—Body temperature increased—Capecitabine—prostate cancer	0.000134	0.00033	CcSEcCtD
Pentoxifylline—Vomiting—Etoposide—prostate cancer	0.000134	0.00033	CcSEcCtD
Pentoxifylline—Erythema—Doxorubicin—prostate cancer	0.000134	0.00033	CcSEcCtD
Pentoxifylline—Anaemia—Epirubicin—prostate cancer	0.000134	0.000329	CcSEcCtD
Pentoxifylline—Agitation—Epirubicin—prostate cancer	0.000133	0.000328	CcSEcCtD
Pentoxifylline—Dyspepsia—Prednisone—prostate cancer	0.000133	0.000327	CcSEcCtD
Pentoxifylline—Rash—Etoposide—prostate cancer	0.000133	0.000327	CcSEcCtD
Pentoxifylline—Dermatitis—Etoposide—prostate cancer	0.000133	0.000327	CcSEcCtD
Pentoxifylline—Headache—Etoposide—prostate cancer	0.000132	0.000325	CcSEcCtD
Pentoxifylline—Flatulence—Doxorubicin—prostate cancer	0.000132	0.000325	CcSEcCtD
Pentoxifylline—Tension—Doxorubicin—prostate cancer	0.000132	0.000324	CcSEcCtD
Pentoxifylline—Decreased appetite—Prednisone—prostate cancer	0.000131	0.000323	CcSEcCtD
Pentoxifylline—Dysgeusia—Doxorubicin—prostate cancer	0.000131	0.000323	CcSEcCtD
Pentoxifylline—Malaise—Epirubicin—prostate cancer	0.000131	0.000321	CcSEcCtD
Pentoxifylline—Nervousness—Doxorubicin—prostate cancer	0.00013	0.00032	CcSEcCtD
Pentoxifylline—Leukopenia—Epirubicin—prostate cancer	0.00013	0.000319	CcSEcCtD
Pentoxifylline—Back pain—Doxorubicin—prostate cancer	0.00013	0.000319	CcSEcCtD
Pentoxifylline—Constipation—Prednisone—prostate cancer	0.000129	0.000318	CcSEcCtD
Pentoxifylline—Hypersensitivity—Docetaxel—prostate cancer	0.000129	0.000318	CcSEcCtD
Pentoxifylline—Muscle spasms—Doxorubicin—prostate cancer	0.000129	0.000317	CcSEcCtD
Pentoxifylline—Palpitations—Epirubicin—prostate cancer	0.000128	0.000315	CcSEcCtD
Pentoxifylline—Vision blurred—Doxorubicin—prostate cancer	0.000126	0.000311	CcSEcCtD
Pentoxifylline—Asthenia—Docetaxel—prostate cancer	0.000126	0.000309	CcSEcCtD
Pentoxifylline—Convulsion—Epirubicin—prostate cancer	0.000125	0.000309	CcSEcCtD
Pentoxifylline—Nausea—Etoposide—prostate cancer	0.000125	0.000308	CcSEcCtD
Pentoxifylline—Hypertension—Epirubicin—prostate cancer	0.000125	0.000308	CcSEcCtD
Pentoxifylline—Hypersensitivity—Capecitabine—prostate cancer	0.000125	0.000308	CcSEcCtD
Pentoxifylline—Feeling abnormal—Prednisone—prostate cancer	0.000125	0.000307	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Doxorubicin—prostate cancer	0.000124	0.000306	CcSEcCtD
Pentoxifylline—Pruritus—Docetaxel—prostate cancer	0.000124	0.000305	CcSEcCtD
Pentoxifylline—Anaemia—Doxorubicin—prostate cancer	0.000124	0.000305	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Prednisone—prostate cancer	0.000124	0.000304	CcSEcCtD
Pentoxifylline—Chest pain—Epirubicin—prostate cancer	0.000123	0.000304	CcSEcCtD
Pentoxifylline—Myalgia—Epirubicin—prostate cancer	0.000123	0.000304	CcSEcCtD
Pentoxifylline—Agitation—Doxorubicin—prostate cancer	0.000123	0.000303	CcSEcCtD
Pentoxifylline—Anxiety—Epirubicin—prostate cancer	0.000123	0.000302	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000122	0.000301	CcSEcCtD
Pentoxifylline—Discomfort—Epirubicin—prostate cancer	0.000122	0.0003	CcSEcCtD
Pentoxifylline—Asthenia—Capecitabine—prostate cancer	0.000122	0.0003	CcSEcCtD
Pentoxifylline—Malaise—Doxorubicin—prostate cancer	0.000121	0.000297	CcSEcCtD
Pentoxifylline—Dry mouth—Epirubicin—prostate cancer	0.000121	0.000297	CcSEcCtD
Pentoxifylline—Urticaria—Prednisone—prostate cancer	0.00012	0.000296	CcSEcCtD
Pentoxifylline—Pruritus—Capecitabine—prostate cancer	0.00012	0.000295	CcSEcCtD
Pentoxifylline—Leukopenia—Doxorubicin—prostate cancer	0.00012	0.000295	CcSEcCtD
Pentoxifylline—Diarrhoea—Docetaxel—prostate cancer	0.00012	0.000295	CcSEcCtD
Pentoxifylline—Body temperature increased—Prednisone—prostate cancer	0.000119	0.000294	CcSEcCtD
Pentoxifylline—Abdominal pain—Prednisone—prostate cancer	0.000119	0.000294	CcSEcCtD
Pentoxifylline—Confusional state—Epirubicin—prostate cancer	0.000119	0.000293	CcSEcCtD
Pentoxifylline—Palpitations—Doxorubicin—prostate cancer	0.000118	0.000291	CcSEcCtD
Pentoxifylline—Oedema—Epirubicin—prostate cancer	0.000118	0.000291	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Epirubicin—prostate cancer	0.000118	0.000291	CcSEcCtD
Pentoxifylline—Infection—Epirubicin—prostate cancer	0.000117	0.000289	CcSEcCtD
Pentoxifylline—Shock—Epirubicin—prostate cancer	0.000116	0.000286	CcSEcCtD
Pentoxifylline—Convulsion—Doxorubicin—prostate cancer	0.000116	0.000286	CcSEcCtD
Pentoxifylline—Diarrhoea—Capecitabine—prostate cancer	0.000116	0.000286	CcSEcCtD
Pentoxifylline—Dizziness—Docetaxel—prostate cancer	0.000116	0.000285	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Epirubicin—prostate cancer	0.000116	0.000285	CcSEcCtD
Pentoxifylline—Hypertension—Doxorubicin—prostate cancer	0.000116	0.000285	CcSEcCtD
Pentoxifylline—Tachycardia—Epirubicin—prostate cancer	0.000115	0.000284	CcSEcCtD
Pentoxifylline—Skin disorder—Epirubicin—prostate cancer	0.000115	0.000283	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Epirubicin—prostate cancer	0.000114	0.000281	CcSEcCtD
Pentoxifylline—Chest pain—Doxorubicin—prostate cancer	0.000114	0.000281	CcSEcCtD
Pentoxifylline—Myalgia—Doxorubicin—prostate cancer	0.000114	0.000281	CcSEcCtD
Pentoxifylline—Anxiety—Doxorubicin—prostate cancer	0.000114	0.00028	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000113	0.000279	CcSEcCtD
Pentoxifylline—Discomfort—Doxorubicin—prostate cancer	0.000113	0.000277	CcSEcCtD
Pentoxifylline—Anorexia—Epirubicin—prostate cancer	0.000113	0.000277	CcSEcCtD
Pentoxifylline—Dizziness—Capecitabine—prostate cancer	0.000112	0.000276	CcSEcCtD
Pentoxifylline—Dry mouth—Doxorubicin—prostate cancer	0.000112	0.000275	CcSEcCtD
Pentoxifylline—Vomiting—Docetaxel—prostate cancer	0.000111	0.000274	CcSEcCtD
Pentoxifylline—Hypersensitivity—Prednisone—prostate cancer	0.000111	0.000274	CcSEcCtD
Pentoxifylline—Rash—Docetaxel—prostate cancer	0.00011	0.000272	CcSEcCtD
Pentoxifylline—Hypotension—Epirubicin—prostate cancer	0.00011	0.000272	CcSEcCtD
Pentoxifylline—Dermatitis—Docetaxel—prostate cancer	0.00011	0.000272	CcSEcCtD
Pentoxifylline—Confusional state—Doxorubicin—prostate cancer	0.00011	0.000271	CcSEcCtD
Pentoxifylline—Headache—Docetaxel—prostate cancer	0.00011	0.00027	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Doxorubicin—prostate cancer	0.000109	0.000269	CcSEcCtD
Pentoxifylline—Oedema—Doxorubicin—prostate cancer	0.000109	0.000269	CcSEcCtD
Pentoxifylline—Infection—Doxorubicin—prostate cancer	0.000109	0.000267	CcSEcCtD
Pentoxifylline—Asthenia—Prednisone—prostate cancer	0.000108	0.000267	CcSEcCtD
Pentoxifylline—Vomiting—Capecitabine—prostate cancer	0.000108	0.000266	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000108	0.000265	CcSEcCtD
Pentoxifylline—Shock—Doxorubicin—prostate cancer	0.000108	0.000265	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Doxorubicin—prostate cancer	0.000107	0.000264	CcSEcCtD
Pentoxifylline—Rash—Capecitabine—prostate cancer	0.000107	0.000263	CcSEcCtD
Pentoxifylline—Pruritus—Prednisone—prostate cancer	0.000107	0.000263	CcSEcCtD
Pentoxifylline—Insomnia—Epirubicin—prostate cancer	0.000107	0.000263	CcSEcCtD
Pentoxifylline—Dermatitis—Capecitabine—prostate cancer	0.000107	0.000263	CcSEcCtD
Pentoxifylline—Tachycardia—Doxorubicin—prostate cancer	0.000107	0.000263	CcSEcCtD
Pentoxifylline—Headache—Capecitabine—prostate cancer	0.000106	0.000262	CcSEcCtD
Pentoxifylline—Skin disorder—Doxorubicin—prostate cancer	0.000106	0.000261	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Doxorubicin—prostate cancer	0.000106	0.00026	CcSEcCtD
Pentoxifylline—Dyspnoea—Epirubicin—prostate cancer	0.000105	0.000259	CcSEcCtD
Pentoxifylline—Somnolence—Epirubicin—prostate cancer	0.000105	0.000259	CcSEcCtD
Pentoxifylline—Anorexia—Doxorubicin—prostate cancer	0.000104	0.000257	CcSEcCtD
Pentoxifylline—Nausea—Docetaxel—prostate cancer	0.000104	0.000256	CcSEcCtD
Pentoxifylline—Dyspepsia—Epirubicin—prostate cancer	0.000104	0.000256	CcSEcCtD
Pentoxifylline—Diarrhoea—Prednisone—prostate cancer	0.000103	0.000255	CcSEcCtD
Pentoxifylline—Decreased appetite—Epirubicin—prostate cancer	0.000103	0.000253	CcSEcCtD
Pentoxifylline—Hypotension—Doxorubicin—prostate cancer	0.000102	0.000252	CcSEcCtD
Pentoxifylline—Constipation—Epirubicin—prostate cancer	0.000101	0.000249	CcSEcCtD
Pentoxifylline—Nausea—Capecitabine—prostate cancer	0.000101	0.000248	CcSEcCtD
Pentoxifylline—Dizziness—Prednisone—prostate cancer	9.99e-05	0.000246	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Doxorubicin—prostate cancer	9.96e-05	0.000245	CcSEcCtD
Pentoxifylline—Insomnia—Doxorubicin—prostate cancer	9.89e-05	0.000243	CcSEcCtD
Pentoxifylline—Dyspnoea—Doxorubicin—prostate cancer	9.75e-05	0.00024	CcSEcCtD
Pentoxifylline—Feeling abnormal—Epirubicin—prostate cancer	9.74e-05	0.00024	CcSEcCtD
Pentoxifylline—Somnolence—Doxorubicin—prostate cancer	9.72e-05	0.000239	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Epirubicin—prostate cancer	9.67e-05	0.000238	CcSEcCtD
Pentoxifylline—Dyspepsia—Doxorubicin—prostate cancer	9.63e-05	0.000237	CcSEcCtD
Pentoxifylline—Vomiting—Prednisone—prostate cancer	9.61e-05	0.000237	CcSEcCtD
Pentoxifylline—Rash—Prednisone—prostate cancer	9.53e-05	0.000235	CcSEcCtD
Pentoxifylline—Dermatitis—Prednisone—prostate cancer	9.52e-05	0.000234	CcSEcCtD
Pentoxifylline—Decreased appetite—Doxorubicin—prostate cancer	9.51e-05	0.000234	CcSEcCtD
Pentoxifylline—Headache—Prednisone—prostate cancer	9.47e-05	0.000233	CcSEcCtD
Pentoxifylline—Urticaria—Epirubicin—prostate cancer	9.39e-05	0.000231	CcSEcCtD
Pentoxifylline—Constipation—Doxorubicin—prostate cancer	9.35e-05	0.00023	CcSEcCtD
Pentoxifylline—Abdominal pain—Epirubicin—prostate cancer	9.34e-05	0.00023	CcSEcCtD
Pentoxifylline—Body temperature increased—Epirubicin—prostate cancer	9.34e-05	0.00023	CcSEcCtD
Pentoxifylline—Feeling abnormal—Doxorubicin—prostate cancer	9.01e-05	0.000222	CcSEcCtD
Pentoxifylline—Nausea—Prednisone—prostate cancer	8.98e-05	0.000221	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Doxorubicin—prostate cancer	8.94e-05	0.00022	CcSEcCtD
Pentoxifylline—Hypersensitivity—Epirubicin—prostate cancer	8.71e-05	0.000214	CcSEcCtD
Pentoxifylline—Urticaria—Doxorubicin—prostate cancer	8.69e-05	0.000214	CcSEcCtD
Pentoxifylline—Body temperature increased—Doxorubicin—prostate cancer	8.65e-05	0.000213	CcSEcCtD
Pentoxifylline—Abdominal pain—Doxorubicin—prostate cancer	8.65e-05	0.000213	CcSEcCtD
Pentoxifylline—Asthenia—Epirubicin—prostate cancer	8.48e-05	0.000209	CcSEcCtD
Pentoxifylline—Pruritus—Epirubicin—prostate cancer	8.36e-05	0.000206	CcSEcCtD
Pentoxifylline—Diarrhoea—Epirubicin—prostate cancer	8.09e-05	0.000199	CcSEcCtD
Pentoxifylline—Hypersensitivity—Doxorubicin—prostate cancer	8.06e-05	0.000198	CcSEcCtD
Pentoxifylline—Asthenia—Doxorubicin—prostate cancer	7.85e-05	0.000193	CcSEcCtD
Pentoxifylline—Dizziness—Epirubicin—prostate cancer	7.82e-05	0.000192	CcSEcCtD
Pentoxifylline—Pruritus—Doxorubicin—prostate cancer	7.74e-05	0.00019	CcSEcCtD
Pentoxifylline—Vomiting—Epirubicin—prostate cancer	7.52e-05	0.000185	CcSEcCtD
Pentoxifylline—Diarrhoea—Doxorubicin—prostate cancer	7.48e-05	0.000184	CcSEcCtD
Pentoxifylline—Rash—Epirubicin—prostate cancer	7.45e-05	0.000183	CcSEcCtD
Pentoxifylline—Dermatitis—Epirubicin—prostate cancer	7.45e-05	0.000183	CcSEcCtD
Pentoxifylline—Headache—Epirubicin—prostate cancer	7.4e-05	0.000182	CcSEcCtD
Pentoxifylline—Dizziness—Doxorubicin—prostate cancer	7.23e-05	0.000178	CcSEcCtD
Pentoxifylline—Nausea—Epirubicin—prostate cancer	7.02e-05	0.000173	CcSEcCtD
Pentoxifylline—Vomiting—Doxorubicin—prostate cancer	6.95e-05	0.000171	CcSEcCtD
Pentoxifylline—Rash—Doxorubicin—prostate cancer	6.9e-05	0.00017	CcSEcCtD
Pentoxifylline—Dermatitis—Doxorubicin—prostate cancer	6.89e-05	0.00017	CcSEcCtD
Pentoxifylline—Headache—Doxorubicin—prostate cancer	6.85e-05	0.000169	CcSEcCtD
Pentoxifylline—Nausea—Doxorubicin—prostate cancer	6.5e-05	0.00016	CcSEcCtD
Pentoxifylline—ADORA1—Signaling Pathways—SERPINE1—prostate cancer	1.66e-05	6.65e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CD—prostate cancer	1.66e-05	6.64e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LDHB—prostate cancer	1.65e-05	6.63e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CXCL8—prostate cancer	1.65e-05	6.62e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—JAK2—prostate cancer	1.64e-05	6.59e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—KRAS—prostate cancer	1.64e-05	6.58e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—PIK3CA—prostate cancer	1.64e-05	6.58e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SERPINE1—prostate cancer	1.64e-05	6.57e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—LEP—prostate cancer	1.63e-05	6.54e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP3A5—prostate cancer	1.62e-05	6.51e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—KRAS—prostate cancer	1.62e-05	6.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CAV1—prostate cancer	1.61e-05	6.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CDKN1B—prostate cancer	1.61e-05	6.47e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—PIK3CA—prostate cancer	1.61e-05	6.46e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—FGF2—prostate cancer	1.6e-05	6.44e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MDM2—prostate cancer	1.6e-05	6.43e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KDR—prostate cancer	1.6e-05	6.41e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—AKT1—prostate cancer	1.59e-05	6.4e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—FGF2—prostate cancer	1.58e-05	6.36e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NOS3—prostate cancer	1.58e-05	6.35e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—ERBB2—prostate cancer	1.58e-05	6.34e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CASP3—prostate cancer	1.58e-05	6.34e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL2—prostate cancer	1.58e-05	6.33e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL6—prostate cancer	1.57e-05	6.3e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—TCN2—prostate cancer	1.57e-05	6.28e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PDHA1—prostate cancer	1.57e-05	6.28e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—UCP3—prostate cancer	1.57e-05	6.28e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTA3—prostate cancer	1.57e-05	6.28e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NOS3—prostate cancer	1.56e-05	6.27e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CB—prostate cancer	1.56e-05	6.26e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ESR1—prostate cancer	1.56e-05	6.24e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—JAK2—prostate cancer	1.54e-05	6.17e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCND1—prostate cancer	1.54e-05	6.17e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CTNNB1—prostate cancer	1.52e-05	6.11e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—JAK2—prostate cancer	1.52e-05	6.1e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—BAD—prostate cancer	1.52e-05	6.1e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—PIK3CA—prostate cancer	1.51e-05	6.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MDM2—prostate cancer	1.5e-05	6.02e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CXCL8—prostate cancer	1.5e-05	6.01e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC22A3—prostate cancer	1.49e-05	5.99e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HSD3B1—prostate cancer	1.49e-05	5.99e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MMP9—prostate cancer	1.49e-05	5.99e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—PIK3CA—prostate cancer	1.49e-05	5.97e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CDKN1A—prostate cancer	1.49e-05	5.97e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PTEN—prostate cancer	1.48e-05	5.95e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MDM2—prostate cancer	1.48e-05	5.95e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—ERBB2—prostate cancer	1.48e-05	5.94e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APC—prostate cancer	1.47e-05	5.9e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CG—prostate cancer	1.47e-05	5.9e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CDKN1B—prostate cancer	1.46e-05	5.87e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—ERBB2—prostate cancer	1.46e-05	5.87e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CB—prostate cancer	1.46e-05	5.86e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGF—prostate cancer	1.45e-05	5.84e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IRS1—prostate cancer	1.45e-05	5.84e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.45e-05	5.82e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—AKT1—prostate cancer	1.45e-05	5.81e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—AKT1—prostate cancer	1.45e-05	5.81e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CB—prostate cancer	1.44e-05	5.79e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CASP3—prostate cancer	1.43e-05	5.75e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—TBXAS1—prostate cancer	1.43e-05	5.75e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTA4—prostate cancer	1.43e-05	5.75e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL2—prostate cancer	1.43e-05	5.75e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—prostate cancer	1.42e-05	5.72e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—EP300—prostate cancer	1.41e-05	5.68e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—GSK3B—prostate cancer	1.41e-05	5.66e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CXCL8—prostate cancer	1.4e-05	5.63e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.4e-05	5.62e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCND1—prostate cancer	1.4e-05	5.6e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTA2—prostate cancer	1.4e-05	5.6e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—INS—prostate cancer	1.39e-05	5.59e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CXCL8—prostate cancer	1.39e-05	5.56e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CTNNB1—prostate cancer	1.38e-05	5.55e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SULT1A1—prostate cancer	1.38e-05	5.53e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCG5—prostate cancer	1.38e-05	5.53e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SRC—prostate cancer	1.38e-05	5.52e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CDKN1B—prostate cancer	1.37e-05	5.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CREBBP—prostate cancer	1.36e-05	5.47e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—AKT1—prostate cancer	1.36e-05	5.44e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MMP9—prostate cancer	1.36e-05	5.44e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CDKN1B—prostate cancer	1.35e-05	5.43e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CDKN1A—prostate cancer	1.35e-05	5.42e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PTEN—prostate cancer	1.35e-05	5.41e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1—prostate cancer	1.35e-05	5.41e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTA1—prostate cancer	1.35e-05	5.4e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CASP3—prostate cancer	1.34e-05	5.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL2—prostate cancer	1.34e-05	5.38e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—EGFR—prostate cancer	1.34e-05	5.38e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—VEGFA—prostate cancer	1.34e-05	5.38e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—AKT1—prostate cancer	1.34e-05	5.37e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—prostate cancer	1.33e-05	5.35e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HSD3B2—prostate cancer	1.33e-05	5.34e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTO1—prostate cancer	1.33e-05	5.34e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NAT2—prostate cancer	1.33e-05	5.34e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—STAT3—prostate cancer	1.33e-05	5.32e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CASP3—prostate cancer	1.33e-05	5.32e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL2—prostate cancer	1.32e-05	5.32e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—prostate cancer	1.32e-05	5.29e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—AKT1—prostate cancer	1.31e-05	5.27e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCND1—prostate cancer	1.31e-05	5.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAP2K1—prostate cancer	1.3e-05	5.22e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CTNNB1—prostate cancer	1.29e-05	5.19e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CD—prostate cancer	1.29e-05	5.19e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCND1—prostate cancer	1.29e-05	5.18e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—EP300—prostate cancer	1.28e-05	5.16e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.28e-05	5.14e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.28e-05	5.14e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SERPINE1—prostate cancer	1.28e-05	5.13e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CTNNB1—prostate cancer	1.28e-05	5.13e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP2C18—prostate cancer	1.28e-05	5.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LRP2—prostate cancer	1.28e-05	5.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PLCB2—prostate cancer	1.28e-05	5.12e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MMP9—prostate cancer	1.27e-05	5.09e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—KRAS—prostate cancer	1.27e-05	5.08e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CDKN1A—prostate cancer	1.26e-05	5.07e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PTEN—prostate cancer	1.26e-05	5.06e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP9—prostate cancer	1.25e-05	5.03e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—P4HB—prostate cancer	1.25e-05	5.02e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CDKN1A—prostate cancer	1.25e-05	5.01e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SRC—prostate cancer	1.25e-05	5.01e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PTEN—prostate cancer	1.25e-05	5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—FGF2—prostate cancer	1.24e-05	4.97e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MYC—prostate cancer	1.23e-05	4.95e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—AKT1—prostate cancer	1.23e-05	4.94e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TGFB1—prostate cancer	1.23e-05	4.94e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NOS3—prostate cancer	1.22e-05	4.9e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC22A1—prostate cancer	1.22e-05	4.89e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—VEGFA—prostate cancer	1.22e-05	4.88e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—AKT1—prostate cancer	1.22e-05	4.88e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—EGFR—prostate cancer	1.21e-05	4.84e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—STAT3—prostate cancer	1.2e-05	4.84e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.2e-05	4.83e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EP300—prostate cancer	1.2e-05	4.83e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EP300—prostate cancer	1.19e-05	4.77e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—JAK2—prostate cancer	1.19e-05	4.76e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SULT2A1—prostate cancer	1.19e-05	4.76e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SRC—prostate cancer	1.17e-05	4.69e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MED12—prostate cancer	1.17e-05	4.68e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PIK3CA—prostate cancer	1.16e-05	4.67e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MDM2—prostate cancer	1.16e-05	4.65e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GNG5—prostate cancer	1.16e-05	4.65e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SRC—prostate cancer	1.16e-05	4.64e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ERBB2—prostate cancer	1.14e-05	4.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—VEGFA—prostate cancer	1.14e-05	4.57e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—KRAS—prostate cancer	1.14e-05	4.57e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—STAT3—prostate cancer	1.13e-05	4.53e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CB—prostate cancer	1.13e-05	4.52e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—VEGFA—prostate cancer	1.13e-05	4.52e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MYC—prostate cancer	1.12e-05	4.49e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TGFB1—prostate cancer	1.12e-05	4.48e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOA3—prostate cancer	1.12e-05	4.48e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—STAT3—prostate cancer	1.11e-05	4.47e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.1e-05	4.4e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—EGFR—prostate cancer	1.1e-05	4.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CXCL8—prostate cancer	1.08e-05	4.35e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HPGDS—prostate cancer	1.06e-05	4.27e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CDKN1B—prostate cancer	1.06e-05	4.25e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP2C19—prostate cancer	1.06e-05	4.24e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MYC—prostate cancer	1.05e-05	4.21e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3CA—prostate cancer	1.05e-05	4.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—AKT1—prostate cancer	1.05e-05	4.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TGFB1—prostate cancer	1.05e-05	4.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CASP3—prostate cancer	1.04e-05	4.16e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MYC—prostate cancer	1.04e-05	4.16e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL2—prostate cancer	1.04e-05	4.15e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—KRAS—prostate cancer	1.03e-05	4.15e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TGFB1—prostate cancer	1.03e-05	4.15e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTT1—prostate cancer	1.03e-05	4.14e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ACHE—prostate cancer	1.03e-05	4.14e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—prostate cancer	1.03e-05	4.13e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EGFR—prostate cancer	1.03e-05	4.11e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP2A6—prostate cancer	1.02e-05	4.09e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.02e-05	4.08e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EGFR—prostate cancer	1.01e-05	4.07e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TP53—prostate cancer	1.01e-05	4.06e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCND1—prostate cancer	1.01e-05	4.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CTNNB1—prostate cancer	9.99e-06	4.01e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AKR1C3—prostate cancer	9.93e-06	3.98e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PRKACB—prostate cancer	9.87e-06	3.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP9—prostate cancer	9.8e-06	3.93e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP17A1—prostate cancer	9.77e-06	3.92e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CDKN1A—prostate cancer	9.76e-06	3.92e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PTEN—prostate cancer	9.74e-06	3.91e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—KRAS—prostate cancer	9.69e-06	3.89e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	9.64e-06	3.87e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—KRAS—prostate cancer	9.57e-06	3.84e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CA—prostate cancer	9.5e-06	3.81e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—AKT1—prostate cancer	9.5e-06	3.81e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOA2—prostate cancer	9.31e-06	3.74e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EP300—prostate cancer	9.29e-06	3.73e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—prostate cancer	9.27e-06	3.72e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TP53—prostate cancer	9.19e-06	3.69e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SRC—prostate cancer	9.03e-06	3.62e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CA—prostate cancer	8.9e-06	3.57e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC5A5—prostate cancer	8.88e-06	3.56e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—VEGFA—prostate cancer	8.8e-06	3.53e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CA—prostate cancer	8.79e-06	3.53e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—STAT3—prostate cancer	8.71e-06	3.5e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP2E1—prostate cancer	8.68e-06	3.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TP53—prostate cancer	8.61e-06	3.46e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NQO1—prostate cancer	8.58e-06	3.44e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—AKT1—prostate cancer	8.55e-06	3.43e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TP53—prostate cancer	8.51e-06	3.41e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—TH—prostate cancer	8.46e-06	3.39e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—prostate cancer	8.42e-06	3.38e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	8.4e-06	3.37e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP3A4—prostate cancer	8.37e-06	3.36e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	8.32e-06	3.34e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP1B1—prostate cancer	8.23e-06	3.3e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MYC—prostate cancer	8.09e-06	3.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TGFB1—prostate cancer	8.07e-06	3.24e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GGT1—prostate cancer	7.97e-06	3.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGFR—prostate cancer	7.92e-06	3.18e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—prostate cancer	7.88e-06	3.16e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOA1—prostate cancer	7.85e-06	3.15e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—prostate cancer	7.79e-06	3.12e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AKT1—prostate cancer	7.76e-06	3.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP19A1—prostate cancer	7.73e-06	3.1e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KRAS—prostate cancer	7.48e-06	3e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—RXRA—prostate cancer	7.46e-06	3e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AKT1—prostate cancer	7.27e-06	2.92e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	7.26e-06	2.91e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—COMT—prostate cancer	7.19e-06	2.89e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AKT1—prostate cancer	7.18e-06	2.88e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTP1—prostate cancer	7.16e-06	2.87e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ITPR1—prostate cancer	7.04e-06	2.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.92e-06	2.78e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CA—prostate cancer	6.87e-06	2.76e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—TYMS—prostate cancer	6.65e-06	2.67e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TP53—prostate cancer	6.65e-06	2.67e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTM1—prostate cancer	6.58e-06	2.64e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LPL—prostate cancer	6.45e-06	2.59e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP1A1—prostate cancer	6.23e-06	2.5e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ERCC2—prostate cancer	6.18e-06	2.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—prostate cancer	6.08e-06	2.44e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MTHFR—prostate cancer	5.81e-06	2.33e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARA—prostate cancer	5.7e-06	2.29e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT1—prostate cancer	5.61e-06	2.25e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CAV1—prostate cancer	5.36e-06	2.15e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.12e-06	2.06e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CG—prostate cancer	4.88e-06	1.96e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—INS—prostate cancer	4.62e-06	1.85e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CREBBP—prostate cancer	4.53e-06	1.82e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CD—prostate cancer	4.29e-06	1.72e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NOS3—prostate cancer	4.05e-06	1.63e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CB—prostate cancer	3.74e-06	1.5e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—prostate cancer	3.71e-06	1.49e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTEN—prostate cancer	3.23e-06	1.3e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—EP300—prostate cancer	3.08e-06	1.24e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CA—prostate cancer	2.28e-06	9.15e-06	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AKT1—prostate cancer	1.86e-06	7.48e-06	CbGpPWpGaD
